HMGCR and cardiovascular disorder: Previous studies established that HMGCR and NPC1L1 gene polymorphisms were associated with baseline LDL-C concentrations [9], and HMGCR inhibitors (statins) and NPC1L1 inhibitors (ezetimibe) can reduce LDL-C concentrations and the risk of cardiovascular disease [4, 10].